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ABSTRACT
Objectives: Early osteoporotic fractures have a great
impact on disease progression, the first fracture being a
major risk factor for further fractures. Strontium ranelate
efficacy against vertebral fractures is presently assessed
in a subset of women aged 50–65 years.
Methods: The Spinal Osteoporosis Therapeutic
Intervention (SOTI) was an international, double blind,
placebo controlled trial, supporting the efficacy of
strontium ranelate 2 g/day in reducing the risk of vertebral
fractures in postmenopausal women with osteoporosis
and a prevalent vertebral fracture. 353 of these randomly
assigned women were included in this analysis.
Results: Over 4 years, strontium ranelate significantly
reduced the risk of vertebral fracture by 35% (relative risk
0.65; 95% CI 0.42 to 0.99, p,0.05). In the strontium
ranelate group, the bone mineral density increased from
baseline by 15.8% at lumbar spine and 7.1% at femoral
neck.
Conclusion: These data demonstrate a significant
vertebral antifracture efficacy of strontium ranelate in
young postmenopausal women aged 50–65 years with
severe osteoporosis and confirm the efficacy of this
antiosteoporotic treatment to prevent vertebral fractures,
whatever the age of the patient.
Vertebral fractures represent 27% of all osteoporo-
tic fractures coming to clinical attention
1 and their
deleterious consequences on health are now well
recognised. Clinical vertebral fractures increase
mortality in the elderly.
23 Prevalent vertebral
fractures increase the risk of subsequent vertebral
and non-vertebral fractures,
34as well as the risk of
hip fracture with at least a twofold excess. The risk
of further fracturing has been shown to be higher
among younger people compared with the elderly.
4
Few data are available in clinical trials in patients
younger than 65 years.
Strontium ranelate is an antiosteoporotic treat-
ment that decreases the risk of vertebral
5 and non-
vertebral fractures,
6 including the risk of hip
fractures in a high-risk population.
6 The aim of
the present study was to assess the efficacy of
strontium ranelate in patients with osteoporosis
aged 50–65 years, most presenting with a prevalent
vertebral fracture, a subgroup of patients having a
very high lifetime risk of fractures.
MATERIALS AND METHODS
Study subjects
Data from the Spinal Osteoporosis Therapeutic
Intervention (SOTI) trial were used for this
study. In this randomised, double blind, placebo
controlled clinical trial, 1649 postmenopausal
patients aged 50 years or more were enrolled with
these inclusion criteria: at least one vertebral
fracture and a lumbar spine bone mineral density
(BMD) of 0.840 g/cm
2 or less. The vertebral
fracture incidence was the main efficacy criterion
of the study. The assessment of this criterion was
performed over 3 years (main statistical analysis)
showing an early and sustained significant reduc-
tion in the vertebral fracture risk by 49% over the
first year and by 41% over 3 years.
5 Furthermore, a
pre-planned analysis was performed over 4 years
showing a 33% reduction (relative risk (RR) 0.67;
95% CI 0.55 to 0.81, p,0.001) in the risk of
sustaining a vertebral fracture over 4 years (data on
file).
For this post-hoc analysis investigating, blinded
to treatment, the antifracture efficacy of strontium
ranelate in younger postmenopausal women with
osteoporosis, we selected the subset of the SOTI
study population aged 50–65 years.
Treatment regimens
Patients were randomly assigned to receive 2 g per
day of strontium ranelate or placebo. Throughout
the study period, subjects received daily calcium
and vitamin D supplements at lunchtime.
Assessment of outcomes
Radiographs of the spine were obtained at baseline
and annually and assessed centrally. A semiquan-
titative visual assessment of each vertebrae from
T4 to L4 was performed by the same reader
throughout the study, using the semiquantita-
tive grading scale as previously described by
Genant et al.
7
BMD at the lumbar spine and proximal femur
was measured by dual-energy x ray absorptiometry
at baseline and at 6-month intervals. For patient
diagnostic categorisation, lumbar spine and
femoral neck BMD T-scores were calculated using
a reference population previously described.
8
Femoral neck BMD T-scores were also re-
calculated using the National Health and
Nutrition Examination Survey III (NHANES III)
reference.
Statistical analysis
The primary endpoint of this analysis was the
incidence in patients experiencing a new vertebral
fracture, estimated according to the Kaplan–Meier
method, and an adjusted Cox model was used to
compare groups and to estimate the RR of
experiencing a new vertebral fracture and its 95%
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The adjusted Cox model considered the treatment effects and
the following covariates: country, L2/L4 BMD at baseline and
prevalent vertebral fractures.
RESULTS
Among the patients included in the SOTI study, 385 were aged
50–65 years, of whom 353 were eligible for the assessment of
the efficacy of strontium ranelate on vertebral fractures
according to the intention-to-treat principle (at least one sachet
intake, at least one assessable vertebral x ray at baseline and one
post-baseline). Baseline characteristics of this population are
presented in table 1. There was no statistically significant
difference between the patients given 2 g/day strontium
ranelate (N = 168) and those given placebo (N = 185).
Over 3 years, treatment with strontium ranelate significantly
reduced the risk of vertebral fracture by 43% (RR 0.57; 95% CI
0.36 to 0.92, p=0.019), with an incidence of vertebral fractures
of 16.9% in the strontium ranelate group versus 29.6% in the
placebo group. This efficacy in reducing the risk of vertebral
fractures was sustained over 4 years of treatment with
strontium ranelate, with a reduction by 35% (RR 0.65, 95%
CI 0.42 to 0.99, p=0.049) and an incidence of vertebral
fractures of 21.6% in the strontium ranelate group versus
32.8% in the placebo group. There was a trend towards a
reduction in the risk of vertebral fracture over the first year,
which was not statistically significant (fig 1). A significant
effect of strontium ranelate compared with placebo was also
observed regarding symptomatic vertebral fractures (defined as
radiological fractures plus concomitant back pain or a decrease
in body height by at least 1 cm) with a 54% reduction in the risk
of symptomatic vertebral fracture over 3 years (RR 0.46; 95% CI
0.22 to 0.97, p=0.033), sustained over 4 years with a 52%
reduction (RR 0.48; 95% CI 0.24 to 0.95, p=0.030). There was
no difference in the incidence of non-vertebral fractures
between groups over 4 years (14.5% and 14.6% in the treated
and placebo groups, respectively).
As shown in fig 2, the BMD mean change from baseline over
3 years at the spine and hip sites was 11.8% and 4.5%,
respectively, for the strontium ranelate-treated group, and
22.8% and 23.0% at these two sites in the placebo group.
Over 4 years, BMD increased further in the strontium ranelate
Table 1 Baseline characteristics of patients
Placebo Strontium ranelate
p Value* N = 185 N = 168
Age, years 60 (3.4) 60 (3.6) NS
Years since menopause 13.4 (6.1) 13.5 (6.0) NS
BMI (kg/m
2) 26.1 26.7 NS
>1 Prevalent vertebral fracture (%) 153 (82.7) 131 (78.0) NS
Previous non-vertebral fracture (%) 50 (27.0) 31 (18.5) NS
Bone mineral density
Lumbar spine T score 23.7 (1.0) 23.5 (1.2) NS
Femoral neck T score 22.5 (0.8) 22.5 (0.8)
Femoral neck T score (NHANES III reference) 21.92 21.92
Data are presented as mean values (SD).
*Wilcoxon test between the two groups of treatment.
BMI, body mass index; NHANES, National Health and Nutrition Examination Survey III.
Figure 1 Incidence of vertebral fractures over the study period
(1 (M12), 3 (M36) and 4 (M48) years data). RR, relative risk.
 
Figure 2 Changes in spine and hip bone mineral density over 4 years in
postmenopausal women with osteoporosis aged 50–65 years receiving
either placebo or strontium ranelate.
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hip, whereas it remained lower than baseline values in the
placebo group, with mean changes of 22.4% and 22.8% at
these two sites (significant difference between groups, p,0.001
at both sites).
Over the 4-year follow-up, clinical, serious, drug-related
adverse effects were similar in the placebo and treated groups
(no clinical significance between groups regarding the incidence
of nausea, diarrhoea, headache, dermatitis, eczema, venous
thromboembolism events) and the overall safety profile was
very similar to that already described for the whole SOTI study
population over 3 and 4 years. No case of pulmonary embolism
or hypersensitivity reaction was observed in this study
population.
DISCUSSION
This study shows that strontium ranelate (2 g/day) decreases
the risk of vertebral fractures over 4 years in women aged 50–
65 years with severe osteoporosis.
The fracture incidence increases with age, but young
postmenopausal women experience fractures. In the National
Osteoporosis Risk Assessment (NORA) study, 37% of the
fractures occurred in women 50–64 years of age, and this
population of young postmenopausal women accounted for
one-fifth of the hip fractures that occurred within 1 year of
baseline.
9 A prevalent fracture may be a much more severe
predictor of subsequent fractures than other well-known risk
factors when considering younger populations at risk due to the
fact that the prevalence of fractures largely increases with age.
Such a prevalent fracture is more common in communities aged
70 or 80 years than in younger populations, giving less weight in
terms of risk to this factor in the elderly.
10 In addition, it has
been shown in a general semi-urban population that the
presence of vertebral fractures led to a decrease in the expected
remaining life years, the decrease being greater in the younger
than in the older age groups.
11 This highlights the importance of
diagnosing and treating appropriately as soon as possible this
youngest postmenopausal population at high further risk.
In the present study, the incidence of vertebral and non-
vertebral fractures over 4 years in the placebo group was high
(32.8% and 14.6%, respectively). This demonstrates in this
population aged less than 65 years that the presence of
prevalent fractures leads to a dramatic increase in the overall
fracture risk, not limited to vertebral fractures. Over the first
year, the incidence of vertebral fractures was 8.3%, which
reinforces the indication of a prompt and effective treatment in
this population.
As strontium is a heavier element than calcium, its presence
in bone could lead to an overestimation of BMD measurement.
However, a strong association has been demonstrated for
strontium ranelate-treated patients between the increase in
total hip and/or femoral neck BMD and the subsequent decrease
in fracture incidence.
12
Few studies are available with other antiosteoporotic drugs in
women aged 50–65 years. The Women’s Health Initiative
showed that treatment with oestrogens alone, or oestrogen
plus progestin, reduces the incidence of fractures compared with
control,
13 but the study was conducted in healthy postmeno-
pausal women. Young age was not a significant factor in
affecting the efficacy of raloxifene, in a population of
postmenopausal women with a prevalence of 37% of vertebral
fractures.
14 Several studies have shown the absence of effect of
age on response to antiosteoporotic treatment, but this point
was assessed either in patients older than 65 years
15 or in a
population with a mean age of 70 years.
16
Our study indicates a significant efficacy of strontium
ranelate in reducing the risk of subsequent vertebral fractures
in young postmenopausal women with severe osteoporosis.
These data together with previous reports confirm the efficacy
of this antiosteoporotic drug at all ages.
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